Please assess the completion status of the following clinical trial:

Trial Title: Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients from age 18 to 65 years ;~2. Male or female;~3. Treatment-naive patients of clinically diagnosed as HBV-induced compensated cirrhosis(meet one of the following two criterions);~   1. endoscopy: esophageal varices , exclusion of noncirrhotic portal hypertension~  2. if no endoscopy,should meet two of the four Criterias:~      * Imaging (US, CT or MRI, et al) showing Surface nodularity: Echogenecity~     * Platelet (PLT) \< 100×10 \< 9 \>/L , no other interpretation~     * Albumin (ALB) \< 35.0 g/L, or International Standard Value (INR) \> 1.3 (Prothrombin Time (PT) prolonged \> 3s), or Cholinesterase (CHE) decrease~     * Liver stiffness measurement value \> 12.4 kpa (ALT\<5×ULN)~4. HBeAg-positive, HBVDNA \> 2×10\<3\> IU/ml or with HBeAg-negative patients, HBVDNA \> 2×10\<2\> IU/ml;~5. Agree to be followed up regularly;~6. Signature of written inform consent.~Exclusion Criteria:~1. Patients with decompensated cirrhosis: including ascites, hepatic encephalopathy, esophageal varices bleeding or other complications of decompensated cirrhosis or hepatocelluar carcinoma;~2. Patients who are allergic to entecavir, thymosin or their components, and those considered not suitable for medicine in this study;~3. Patients with HCV or HIV infection, alcoholic liver disease, autoimmune liver disease, genetic liver disease, drug-induced liver injury, severe non-alcoholic fatty liver disease or other chronic liver diseases;~4. Patients with baseline AFP level higher than 100ng/ml and possible malignant lesion on image, or AFP level higher than 100ng/ml for more than three months;~5. Creatinine \> 1.5×ULN;~6. Patients with other uncured malignant tumors;~7. Patients with severe diseases of heart, lung, kidney, brain, blood system or other organs;~8. Patients with any other reasons not suitable for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Entecavir Therapy (Type: ACTIVE_COMPARATOR): Entecavir, 0.5mg, qd, oral, for 2 years
- Entecavir plus thymosin therapy (Type: EXPERIMENTAL): Entecavir plus thymosin-α 1.6μg, Twice a week, ih, in the middle one year

Based on this trial design, predict the completion outcome and termination type (if applicable).